BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22465658)

  • 1. A systematic study on lyophilization process of polymersomes for long-term storage using doxorubicin-loaded (PEG)₃-PLA nanopolymersomes.
    Ayen WY; Kumar N
    Eur J Pharm Sci; 2012 Aug; 46(5):405-14. PubMed ID: 22465658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
    Anhorn MG; Mahler HC; Langer K
    Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-loaded (PEG)₃-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study.
    Ayen WY; Garkhal K; Kumar N
    Mol Pharm; 2011 Apr; 8(2):466-78. PubMed ID: 21288047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple method to achieve high doxorubicin loading in biodegradable polymersomes.
    Sanson C; Schatz C; Le Meins JF; Soum A; Thévenot J; Garanger E; Lecommandoux S
    J Control Release; 2010 Nov; 147(3):428-35. PubMed ID: 20692308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
    Cheow WS; Ng ML; Kho K; Hadinoto K
    Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
    Essa S; Rabanel JM; Hildgen P
    Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The release behavior of doxorubicin hydrochloride from medicated fibers prepared by emulsion-electrospinning.
    Xu X; Chen X; Ma P; Wang X; Jing X
    Eur J Pharm Biopharm; 2008 Sep; 70(1):165-70. PubMed ID: 18472256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents.
    Ishihara T; Takahashi M; Higaki M; Mizushima Y; Mizushima T
    Int J Pharm; 2010 Jan; 385(1-2):170-5. PubMed ID: 19837147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model.
    Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F
    Eur J Pharm Biopharm; 2015 Aug; 94():521-31. PubMed ID: 26170161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles.
    Howard MD; Lu X; Jay M; Dziubla TD
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1270-9. PubMed ID: 22235767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversibly crosslinked poly(vinyl alcohol) nanoparticles for triggered release of doxorubicin.
    Li Y; Wei R; Ji S; Meng F; Zhong Z
    J Control Release; 2011 Nov; 152 Suppl 1():e54-5. PubMed ID: 22195923
    [No Abstract]   [Full Text] [Related]  

  • 12. Physico-chemical lyophilization behavior of mannitol, human serum albumin formulations.
    Hawe A; Friess W
    Eur J Pharm Sci; 2006 Jun; 28(3):224-32. PubMed ID: 16580820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of highly stabilized curcumin nanoparticles by flash nanoprecipitation and lyophilization.
    Chow SF; Wan KY; Cheng KK; Wong KW; Sun CC; Baum L; Chow AH
    Eur J Pharm Biopharm; 2015 Aug; 94():436-49. PubMed ID: 26143368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability--A step closer from promising technology to application.
    Kasper JC; Schaffert D; Ogris M; Wagner E; Friess W
    J Control Release; 2011 May; 151(3):246-55. PubMed ID: 21223985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability.
    Benival DM; Devarajan PV
    Int J Pharm; 2012 Feb; 423(2):554-61. PubMed ID: 22155412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation Screening and Freeze-Drying Process Optimization of Ginkgolide B Lyophilized Powder for Injection.
    Liu D; Galvanin F; Yu Y
    AAPS PharmSciTech; 2018 Feb; 19(2):541-550. PubMed ID: 28849380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: a stability assessment.
    Hecq JD; Lewis AL; Vanbeckbergen D; Athanosopoulos A; Galanti L; Jamart J; Czuczman P; Chung T
    J Oncol Pharm Pract; 2013 Mar; 19(1):65-74. PubMed ID: 22801955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elution characteristics of doxorubicin-loaded microspheres differ by drug-loading method and microsphere size.
    Kos S; Wasan E; Weir G; Reb P; Cornell C; Ford JA; Liu DM
    J Vasc Interv Radiol; 2011 Mar; 22(3):361-8. PubMed ID: 21353988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.